The U.S. District court for the district of Delaware awarded injunction to Amgen against Sanofi to remove its drug from the market when it was found that Sanofi was infringing Amgen’s drug. Sanofi’s drug ‘Praluent’ was said to infringe Amgen’s counterpart of the same drug, ‘Repatha’ as they both used as they both used an inhibitor of the same protien which is called PCSK9. To Amgen’s suit, the court ordered that the company remove all its drugs from the market causing Sanofi great losses.
Yesterday during the emergency briefings, the court stayed the injunction orered earlier this year. The results of these briefings was that Sanofi could keep selling Praluent for a whole year.